Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

KAT6 inhibitor MEN2312

An orally bioavailable inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon oral administration, KAT6 inhibitor MEN2312 targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation of tumors that overexpress KAT6. KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), commonly amplified genes in solid tumors, play key roles in cell cycle regulation and in tumorigenesis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:KAT6A/B inhibitor MEN2312
KAT6A/KAT6B inhibitor MEN2312
Code name:MEN 2312
MEN-2312
MEN2312
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search